Ascentage Pharma
AAPG
11.97
-0.47
-3.78%
Ascentage Pharma
US · AAPG
#3045 by market cap
Listed 2025
11.97
-0.47
-3.78%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
BTIG Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2025/12/4
-
Rating change
Oppenheimer Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/8/21
-
Rating change
Truist Financial Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $51Market Newswire · 2026/3/27
-
Rating change
B. Riley Securities Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/9/2
-
Rating change
Analysts Offer Insights on NA Companies: Ascentage Pharma Group International Unsponsored ADR (AAPG), Fatpipe, Inc. (FATN) and Aptera Motors Corp. Class B (SEV)TipRanks · 2026/8/21
-
Rating change
Truist Financial Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Cuts Target Price to $22.34Market Newswire · 2026/4/24
-
Citi Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $46Market Newswire · 2026/10/15
-
Rating change
J.P. Morgan Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Cuts Target Price to $46Market Newswire · 2026/4/16
-
Company notice
HyTerra Ltd: AAPG Mid-Continent Sectional Conference PresentationASX · 2025/10/8
-
Rating change
Lucid Capital Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $50Market Newswire · 2025/12/15
-
Citi Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $46Market Newswire · 2026/10/15
-
Rating change
Deutsche Bank Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $40Market Newswire · 2026/4/24
-
Rating change
Truist Financial Maintains Ascentage Pharma(AAPG.US) With Buy RatingMarket Newswire · 2026/8/21
-
Rating change
BTIG Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $48Market Newswire · 2026/3/12
-
Rating change
B. Riley Securities Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $45Market Newswire · 2026/6/10
-
Rating change
Piper Sandler Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/6/1
-
J.P. Morgan Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Cuts Target Price to $33Market Newswire · 2026/10/9
-
Citizens JMP Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $35Market Newswire · 2026/10/14
-
Rating change
Oppenheimer Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $45Market Newswire · 2026/6/15
-
BTIG Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/11/6
-
Rating change
BTIG Maintains Ascentage Pharma(AAPG.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/8/21
-
Rating change
BTIG Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $50Market Newswire · 2025/11/10
-
Rating change
J.P. Morgan Maintains Ascentage Pharma(AAPG.US) With Buy RatingMarket Newswire · 2025/8/22
-
Rating change
Piper Sandler Initiates Ascentage Pharma(AAPG.US) With Buy Rating, Announces Target Price $48Market Newswire · 2025/11/5
-
Rating change
J.P. Morgan Initiates Ascentage Pharma(AAPG.US) With Buy RatingMarket Newswire · 2025/7/28
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Ascentage Pharma discussion 0 comments